Quiver AI Summary Eisai Co., Ltd. and Biogen Inc. have provided an update on the regulatory review of their Alzheimer’s disease treatment, lecanemab, in the European Union.

Eisai and Biogen announced FDA approval for LEQEMBI’s once every four weeks maintenance dosing for Alzheimer’s disease treatment.

Eisai Co (ESAIY) and Biogen Inc. (BIIB) announced that the latest findings for lecanemab-irmb, an anti-amyloid beta protofibril* antibody for the treatment of early Alzheimer’s disease, were ...

Biogen/Eisai’s Alzheimer's drug wins marketing nod in Great Britain Aug. 22, 2024 5:34 AM ET Biogen Inc. (BIIB) Stock, ESALF Stock, ESAIY Stock By: Preeti Singh, SA News Editor 1 Comment ...

Biogen BIIB and Japan-based partner, Eisai, announced an update regarding the regulatory review of an application seeking the approval of Leqembi (lecanemab) for mild cognitive impairment due to ...

Biogen retains biosimilars as Eisai-partnered Leqembi plows ahead amid business pivot Leqembi first got an FDA accelerated approval in January 2023, followed by a traditional nod in July 2023.

Over the weekend, the Food and Drug Administration approved Leqembi, the Alzheimer’s treatment from Eisai and Biogen, for monthly dosing maintenance after patients use it biweekly for 18 months.

Biogen's Leqembi offers hope for Alzheimer's patients by slowing cognitive decline. Patients like Missie Meeks highlight the benefits, but challenges with side effects, insurance, and diagnostics ...

Biogen, Eisai Alzheimer’s drug review delayed in EU Jan. 31, 2025 7:09 AM ET Biogen Inc. (BIIB) Stock, ESALF Stock, ESAIY Stock BRCTF By: Dulan Lokuwithana, SA News Editor 1 Comment Play (2min) ...

We've raised our Biogen fair value estimate to $330 from $305 following lecanemab's strong phase 3 data in Alzheimer’s disease. We had already incorporated a 50% probability of roughly $5 ...

CHICAGO, July 30 (Reuters) - The benefit of Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Alzheimer's drug Leqembi in patients with early-stage Alzheimer's appears to increase ...